Topic summary

Prescription requirements and telehealth models — a second dataset

Sourcing › Regulatory compounding EMA MHRA personal import FDA

This is a generated summary. It shows the 9 most-liked posts from a topic of 95, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.pereiraTL2 Moderator14 Apr 2026#3

micrograms, post #1: On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than anywhere else I have looked. Parcel despatched 13 days ago, tracking last updated 7 days ago at a customs facility, no further… Go to post

post #2 answers the question as asked. The question underneath it is different.

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

24 likes in reply to #1 3mo

j.mwangiTL4 Moderator23 Apr 2026#10

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Coming back to post #8, because the follow-up matters more than the original answer.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

23 likes 3mo

GEldridgeTL3Regular2 May 2026#17

d.eriksen, post #7: Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it. Go to post

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

28 likes in reply to #7 3mo

i.dumitruTL2 Moderator8 May 2026#23

s.kimani, post #9: Picking up post #6: that is the part I would want checked first. Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic. Go to post

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

23 likes in reply to #9 3mo

l.parkinsonTL2Member13 May 2026#28

Coming back to post #26, because the follow-up matters more than the original answer.

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

32 likes 3mo

cohort_driftTL3Regular20 May 2026#36

s.ivaturi, post #25: Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use. Go to post

This follows post #33 rather than contradicting it.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

30 likes in reply to #25 2mo

owen.bradyTL4 Moderator13 Jun 2026#64

Coming back to post #62, because the follow-up matters more than the original answer.

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

25 likes 1mo

n.silvaTL2 Moderator20 Jun 2026#72

This follows post #69 rather than contradicting it.

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

23 likes 1mo

s.grimaldiTL2 Moderator23 Jun 2026#76

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

31 likes 1mo

Read the full topic (95 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Pharmaceutical compounding rules, summarised from primary sources Sourcing › Regulatory MHRA EMA research use only Closed Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…	+135	163	46k	17mo
Coming back to: Research-use-only labelling: what it means and what it does not Sourcing › Regulatory MHRA personal import research use only Solved Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…	+45	50	39k	20mo
What a regulator's shortage notice actually authorises — what changed since Sourcing › Regulatory research use only EMA FDA compounding Solved The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…	+22	26	53k	7mo
Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA MHRA research use only EMA Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…	+72	78	23k	3mo
How compounding permissions changed when supply normalised Sourcing › Regulatory personal import EMA compounding research use only Solved Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised Structured report rather than an opinion, following the format the maintainers asked…	+30	34	51k	16mo

Related topics — sharing the tags compounding, EMA, MHRA

Topic	Participants	Replies	Views	Activity
Hoarding and why it makes a shortage worse Access › Shortages formulary shortage compounding FDA Posting this under the heading it deserves: Hoarding and why it makes a shortage worse Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…		2	12k	22mo
Why this community will not facilitate a group purchase Sourcing › Payments documentation quality payments research use only Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase A logistics question, since the answers here are usually better than anywhere else I have…		2	40k	3mo
Language barriers in accessing a prescription abroad Access › International personal import telehealth EMA Solved Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…		2	22k	1h
Coming back to: Private prescribing in the UK: what is actually involved Regional › UK & Ireland personal import MHRA NHS cost per milligram Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that…	+62	67	2.1k	6mo
What changed in 2026, by region Access › International EMA NHS personal import Solved What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…	+110	122	1.4k	18mo